

# Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria

NCT07256392

---

Status	RECRUITING
Phase	Phase 3
Sponsor	Celldex Therapeutics
Enrollment	1,370 participants

## Key Eligibility Criteria

---

### Inclusion (4)

- Written informed consent
- Must have successfully completed the preceding phase 3 clinical trials (CDX0159-12 or CDX0159-13).
- Both males and females of child-bearing potential must agree to use highly effective contraceptives when receiving barzolvolimab treatment and for 150 days after treatment.
- Willing and able to comply with all study requirements and procedures, including completion of a daily symptom electronic diary.

### Exclusion (4)

- Active pruritic skin condition in addition to CSU.
- Medical condition that would cause additional risk or interfere with study procedures.
- Participants without at least one documented UAS7 score from Weeks 64-68 of the CDX0159-12 or CDX0159-13 trials.
- There are additional criteria that your study doctor will review with you to confirm you are eligible for the study.

## Locations (15 total)

---

Cahaba Dermatology & Skin Health Center, LLC, Birmingham, Alabama, United States  
Center for Dermatology & Plastic Surgery - Avacare, Scottsdale, Arizona, United States  
Dermatology Research Associates, Los Angeles, California, United States  
... and 12 more locations